Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2026)

Sarepta Therapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• In Q1 2026, Raw Materials fell 54.19% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $137.0 million (down 54.19% YoY), while the FY2025 annual figure was $141.3 million, down 49.55% from the prior year.
• Raw Materials for Q1 2026 stood at $137.0 million, down from $141.3 million in the prior quarter.
• The five-year high for Raw Materials was $325.5 million in Q3 2025, with the low at $58.0 million in Q3 2022.
• The 5-year median for Raw Materials is $167.2 million (2024), against an average of $189.1 million.
• The sharpest annual moves came in 2022 and 2023: Raw Materials soared 430.0% in 2022, then slumped 65.56% in 2023.
• Sarepta Therapeutics' Raw Materials stood at $59.2 million in 2022, then jumped by 126.36% to $134.0 million in 2023, then soared by 109.05% to $280.0 million in 2024, then slumped by 49.55% to $141.3 million in 2025, then declined by 3.06% to $137.0 million in 2026.
• Business Quant data shows SRPT's Raw Materials at $137.0 million in Q1 2026, $141.3 million in Q4 2025, and $325.5 million in Q3 2025.